Clinical Trial

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-09-04; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2024-10-25
Trial Details
NCT Number NCT06586957
Lead Sponsor NiKang Therapeutics, Inc.
Conditions Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma +20 more
Enrollment 150 participants
Start Date 2024-09-19
Primary Completion 2029-01 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-21